Health screening helps detect issues early, often before symptoms appear, leading to better outcomes and less pressure on hospitals.
The NHS Lung Cancer Screening Programme is a key part of the NHS’s shift from treatment to prevention, helping reduce health inequalities and improve survival rates through early detection. Xyla, part of Acacium Group, has partnered with Alliance Medical to deliver a nurse-led, patient-focused screening service across South Yorkshire and Bassetlaw, Lancashire and South Cumbria and Shropshire.
Lung cancer remains one of the leading causes of cancer-related deaths in the UK. The national screening programme targets individuals aged 55–74 with a history of smoking. Reaching underserved communities and re-engaging people who don’t respond to a request, especially those aged over 70, has proven difficult.
Barriers such as digital exclusion, cultural and language differences and accessibility issues have limited uptake. Each area needed a solution that would maximise engagement and ensure no one missed the opportunity for life-saving early detection.
Xyla, offered an opportunity to further enhance Alliance Medical’s service delivery and outcomes through a fully managed, clinically robust solution designed to complement existing capabilities.
Xyla’s integration with NHS systems ensures accurate data, seamless communication, patient engagement and support enabling Alliance Medical to focus on clinical delivery.
Our bespoke screening model is designed to overcome engagement barriers and deliver measurable impact:
Xyla increased uptake among non-responders in Bassetlaw by 10%, with 22% of patients booking after receiving a GP-endorsed message. In Fylde & Wyre, the service achieved a 65% conversion rate from invitation to completed Lung Cancer Screening. These results demonstrate the effectiveness of personalised outreach, community engagement and use of a trusted messenger.
The programme detected 763 cancers, including 266 lung cancers, most at early stages (1 & 2). Early diagnosis significantly improves survival rates and reduces the need for intensive treatment. This shift is helping transform outcomes for patients across the region.
Over 97% of patients rated the service positively, citing professionalism, convenience, and compassionate care. Flexible scheduling and culturally sensitive support helped patients feel safe and respected throughout their journey.
Xyla managed over 35,000 appointments and responded to more than 28,000 patient queries. With a ‘did not attend’ (DNA) rate below 4%, the service delivered high throughput and consistent support. This streamlined model reduced pressure on NHS resources while maintaining quality care.
Want to learn how our nurse-led model is transforming lung cancer screening?
Find out moreDiscover how our approach is helping to reach underserved communities, improve outcomes and support NHS productivity.
Fields marked with an * are required.
Have any questions about our services? Whether you’re wondering about how we can help your health goals, or assist your healthcare organisation, we’d love to hear from you.
Get in touchXyla is a trading name of ICS Operations Ltd (Registered No 4793945), Pulse Healthcare Limited (Registered No 3156103), Carehome Selection Limited (Registered No 3091598), Independent Clinical Services Limited (Registered No 4768329) and CHS Healthcare Software Limited (Registered No 11582111)